Prostate Cancer Clinical Trial
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Summary
The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.
Full Description
Treatment with trabectedin will be given once a week for three consecutive weeks with one week of no treatment. This four week period constitutes one cycle.
Trabectedin is given as an infusion through a central venous catheter and is administered over 3 hours.
On day 1 of each cycle a history, physical exam and blood tests will be performed and trabectedin will be administered.
On day 8 and day 15 of each cycle blood work will be performed and trabectedin will be administered.
Patients will continue to receive trabectedin as long as there is no disease progression or unacceptable side effects.
Scans (CT, MRI or bone) or x-rays may be done while the patient is on the trial at the discretion of the physician.
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed adenocarcinoma of the prostate
Radiographically documented metastatic disease
Surgical or chemical castration
Prostate specific antigen (PSA) > 5 ng/ml
Castration resistant prostate cancer (CRPC)
One previous taxane-based chemotherapy regimen
Eastern Cooperative Group (ECOG) performance status 0,1 or 2
Neutrophil count > 1,500/ul
Platelet count > 100,000/ul
Serum bilirubin < 1.0 x upper limit normal (ULN)
Serum alkaline phosphatase < 1.5 x ULN
Asparate aminotransferase/Alanine aminotransferase < 2.5 x ULN
Albumin > 2.5 g/dl
Serum creatinine < 1.5 x ULN
Prior hormonal therapy
Exclusion Criteria:
Chemotherapy treatment within 4 weeks of study entry
Patient not employing adequate contraception
Serious illness or medical conditions, specifically: uncontrolled congestive heart failure or history of myocardial infection or active angina pectoris within 6 months; active infectious process; chronic active liver disease, including chronic hepatitis B, C or cirrhosis
Current anti-cancer treatment with any non-FDA approved investigational drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02115, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.